Ovarian reserve in women with Type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study

Publication Description
Markers of ovarian reserve such as anti-Müllerian hormone (AMH) are used in the management of fertility and prediction of menopause.Although women with type 1 diabetes have a high prevalence of reproductive disorders, no studies have examined whether markers of ovarian reserve are associated with randomization to intensive insulin therapy and subsequent markers of glycemic control.Using data from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study, we found that the strongest predictor of AMH was chronologic age, and that diabetes-specific variables such as randomization to intensive therapy, insulin dose, and glycemic control were not associated with AMH concentrations.

Primary Author
Kim,C.
Dunn,R. L.
Braffett,B.
Cleary,P. A.
Arends,V.
Steffes,M.
Lanham,M. S. M.
Randolph,J. F.
Wessells,H.
Wellons,M. F.
Sarma,A. V.

Volume
33

Issue
5

Start Page
691

Other Pages
692

Publisher
Wiley Subscription Services, Inc

URL
https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.13072

PMID
26798983



Reference Type
Journal Article

Periodical Full
Diabetic medicine

Publication Year
2016

Publication Date
May

Place of Publication
England

ISSN/ISBN
0742-3071

Document Object Index
10.1111/dme.13072